Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Konkret geht es um den Diabetes-Patienten mit kardiovaskulären Erkrankungen oder Risiken, die Herzinsuffizienz sowie die kardiovaskuläre Primär- und Sekundärprävention. Sind Sie hier schon auf dem neuesten Stand? Unsere Experten beleuchten, wo und warum das bisherige Procedere geändert werden soll und was in der Praxis sinnvoll ist. Holen Sie sich Ihr Update und 2 CME-Punkte beim MMW-Webinar am 24. April von 17.30 bis 19 Uhr. 
Erweiterte Suche
Anmelden
nach oben
Osteoporosis International
Erschienen in: Osteoporosis International 2/2010

01.06.2010 | Review

Development and use of FRAX® in osteoporosis

verfasst von: J. A. Kanis, E. V. McCloskey, H. Johansson, A. Oden, O. Ström, F. Borgström

Erschienen in: Osteoporosis International | Sonderheft 2/2010

Einloggen, um Zugang zu erhalten

Abstract

This paper reviews briefly the development and clinical use of FRAX® in the development of assessment guidelines for osteoporosis.
Fractures are the clinical consequence of osteoporosis and are a major cause of morbidity and mortality worldwide. Several treatments are available that have been shown to decrease the risk of fracture, but problems arise in identifying individuals at high fracture risk so that treatments can be effectively targeted. Case finding can be enhanced by the consideration of clinical risk factors that provide information on fracture risk over and above that provided by bone mineral density measurements. The FRAX tool integrates information on fracture risk from clinical risk factors with or without the use of BMD and can be used to improve the targeting of individuals at high fracture risk.
Literatur
1.
Kanis JA, on behalf of the World Health Organization Scientific Group (2008) Assessment of osteoporosis at the primary health-care level. Technical Report. WHO Collaborating Centre, University of Sheffield, UK
2.
Kanis JA, Johnell O, Oden A, Sernbo I, Redlund-Johnell I, Dawson A, de Laet C, Jonsson B (2000) Long-term risk of osteoporotic fractures in Malmo. Osteoporis Int 11:669–674CrossRef
3.
Melton LJ 3rd (2003) Adverse outcomes of osteoporotic fractures in the general population. J Bone Miner Res 18:1139–1141CrossRefPubMed
4.
Kanis JA, Burlet N, Cooper C, on behalf of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) et al (2008) European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 19:399–428CrossRefPubMed
5.
Boonen S, Body JJ, Boutsen Y, Devogelaer JP, Goemaere S, Kaufman JM et al (2005) Evidence-based guidelines for the treatment of postmenopausal osteoporosis: a consensus document of the Belgian Bone Club. Osteoporos Int 16:239–254CrossRefPubMed
6.
Kanis JA (2002) Diagnosis of osteoporosis and assessment of fracture risk. Lancet 359:1929–1936CrossRefPubMed
7.
Hui SL, Slemenda CW, Johnston CC (1988) Age and bone mass as predictors of fracture in a prospective study. J Clin Invest 81:1804–1809CrossRefPubMed
8.
Kanis JA, Johnell O, Oden A, Dawson A, De Laet C, Jonsson B (2001) Ten year probabilities of osteoporotic fractures according to BMD and diagnostic thresholds. Osteoporos Int 12:989–995CrossRefPubMed
9.
Kanis JA, Borgstrom F, De Laet C et al (2005) Assessment of fracture risk. Osteoporos Int 16:581–589CrossRefPubMed
10.
Kanis JA, Black D, Cooper C, Dargent P, Dawson-Hughes B, De Laet C (2002) A new approach to the development of assessment guidelines for osteoporosis. Osteoporosis Int 13:527–536CrossRef
11.
De Laet C, Kanis JA, Oden A et al (2005) Body mass index as a predictor of fracture risk: a meta-analysis. Osteoporos Int 16:1330–1338CrossRefPubMed
12.
Kanis JA, Johnell O, De Laet C et al (2004) A meta-analysis of previous fracture and subsequent fracture risk. Bone 35:375–382CrossRefPubMed
13.
Kanis JA, Johansson H, Oden A et al (2004) A family history of fracture and fracture risk: a meta-analysis. Bone 35:1029–1037CrossRefPubMed
14.
Kanis JA, Johnell O, Oden A et al (2006) Smoking and fracture risk: a meta-analysis. Osteoporos Int 16:155–162CrossRef
15.
Kanis JA, Johansson H, Oden A et al (2000) A meta-analysis of prior corticosteroid use and fracture risk. J Bone Miner Res 19:893–899CrossRef
16.
Kanis JA, Johansson H, Johnell O et al (2005) Alcohol intake as a risk factor for fracture. Osteoporos Int 16:737–742CrossRefPubMed
17.
Kanis JA, Oden A, Johnell O et al (2007) The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women. Osteoporos Int 18:1033–1046CrossRefPubMed
18.
Kanis JA, Johnell O, De Laet C, Jonnson B, Oden A, Ogelsby AK (2002) International variations in hip fracture probability: implications for risk assessment. J Bone Miner Res 17:1237–1244CrossRefPubMed
19.
20.
Kanis JA, McCloskey EV, Johansson H, the National Osteoporosis Guideline Group (2009) Case finding for the management of osteoporosis with FRAX®—assessment and intervention thresholds for the UK. Osteoporos Int 19:1395–1408, Erratum published 2009 Osteoporos Int 20, 499-502CrossRef
21.
Siminoski K, Leslie WD, Frame H et al (2007) Recommendations for bone mineral density reporting in Canada: a shift to absolute fracture risk assessment. J Clin Densitom 10:120–123CrossRefPubMed
22.
Fujiwara S, Nakamura T, Orimo H, Hosoi T, Gorai I, Oden A et al (2008) Development and application of a Japanese model of the WHO fracture risk assessment tool (FRAX™). Osteoporos Int 19:429–448CrossRefPubMed
23.
Kurth AA, Pfeilschifter J (2007) Diagnosis and treatment of postmenopausal osteoporosis and osteoporosis in men. German Guidelines Update 2006. Orthopade 36:683–90, GermanCrossRefPubMed
24.
Dawson-Hughes B, Tosteson AN, Melton LJ 3rd, Baim S, Favus MJ, Khosla S et al (2008) Implications of absolute fracture risk assessment for osteoporosis practice guidelines in the USA. Osteoporos Int 19:449–458CrossRefPubMed
25.
Siris E, Delmas PD (2008) Assessment of 10-year absolute risk: a new paradigm with worldwide application. Osteoporos Int 19:383–384CrossRefPubMed
26.
Johansson H, Kanis JA, Borgström F, Ström O, Svensson O, Mellström D (2010) FRAX® ett stöd för frakturprevention. Läkartidningen, in press
27.
Royal College of Physicians (1999) Osteoporosis: clinical guidelines for the prevention and treatment. Royal College of Physicians, London
28.
Royal College of Physicians and Bone and Tooth Society of Great Britain (2000) Update on pharmacological interventions and an algorithm for management. Royal College of Physicians, London, UK
29.
Royal College of Physicians (2002) Glucocorticoid-induced osteoporosis. Guidelines on prevention and treatment. Bone and Tooth Society of Great Britain, National Osteoporosis Society and Royal College of Physicians. Royal College of Physicians, London, UK
30.
Kanis JA, Adams J, Borgström F, Cooper C, Jönsson B, Preedy D et al (2008) The cost-effectiveness of alendronate in the management of osteoporosis. Bone 42:4–15CrossRefPubMed
31.
Kanis JA, Stevenson M, McCloskey EV, Davis S, Lloyd-Jones M (2007) Glucocorticoid-induced osteoporosis: a systematic review and cost-utility analysis. Health Technol Assess 11:1–256
32.
Kanis JA, Johnell O, on behalf of the Committee of Scientific Advisors of the International Osteoporosis Foundation (2005) Requirements for DXA for the management of osteoporosis in Europe. Osteoporos Int 16:229–238CrossRefPubMed
33.
National Osteoporosis Guideline Group on behalf of the Bone Research Society, British Geriatrics Society, British Society of Rheumatology, Society of Endocrinology, British Orthopaedic Association, Primary Care Rheumatology Society, Osteoporosis 2000 and Osteoporosis Dorset (2008) Osteoporosis: clinical guideline for prevention and treatment. University of Sheffield Press, Sheffield
34.
Tsang SWY, Kanis KAWC, JA JH, Oden A (2009) Ten-year fracture probability in Hong Kong southern Chinese according to age and BMD femoral neck T-scores. Osteoporos Int 20:1939–1945CrossRefPubMed
35.
Czerwiński E, Badurski JE, Marcinowska-Suchowierska E, Osieleniec J (2007) Current understanding of osteoporosis according to the position of the World Health Organization (WHO) and International Osteoporosis Foundation. Ortop Traumatol Rehabil 9:337–356PubMed
36.
Lippuner K, Johansson H, Kanis JA, Rizzoli R (2010) FRAX assessment of osteoporotic fracture probability in Switzerland. Osteoporos Int 21:381–390CrossRefPubMed
37.
Neuprez A, Johansson H, Kanis JA et al (2009) A FRAX model for the assessment of fracture probability in Belgium. Rev Med Liege 64:612–619PubMed
38.
National Osteoporosis Foundation (NOF) (2008) Clinician’s Guide to prevention and treatment of osteoporosis. National Osteoporosis Foundation, National Osteoporosis Foundation Washington www.​nof.​org
39.
Tosteson AN, Melton LJ 3rd, Dawson-Hughes B, Baim S, Favus MJ, Khosla S et al (2008) National Osteoporosis Foundation Guide Committee. Cost-effective osteoporosis treatment thresholds: the United States perspective. Osteoporos Int 19:437–447CrossRefPubMed
40.
Committee for Medicinal Products for Human Use (CHMP) (2006) Guideline on the evaluation of medicinal products in the treatment of primary osteoporosis. Ref CPMP/EWP/552/95Rev.2. London, CHMP
41.
McCloskey EV, Johansson H, Oden A et al (2009) Ten-year fracture probability identifies women who will benefit from clodronate therapy—additional results from a double blind, placebo controlled randomised study. Osteoporos Int 20:811–818CrossRefPubMed
42.
Kanis JA, Johansson H, Oden A, McCloskey EV (2009) Bazedoxifene reduces vertebral and clinical fractures in postmenopausal women at high risk assessed with FRAX®. Bone 44:49–54
Metadaten
Titel
Development and use of FRAX® in osteoporosis
verfasst von
J. A. Kanis
E. V. McCloskey
H. Johansson
A. Oden
O. Ström
F. Borgström
Publikationsdatum
01.06.2010
Verlag
Springer-Verlag
Erschienen in
Osteoporosis International / Ausgabe Sonderheft 2/2010
Print ISSN: 0937-941X
Elektronische ISSN: 1433-2965
DOI
https://doi.org/10.1007/s00198-010-1253-y

Weitere Artikel der Sonderheft 2/2010

Osteoporosis International 2/2010 Zur Ausgabe

Review

Osteoporosis: disease severity and consequent fracture management

Review

Strontium ranelate: an effective solution for diverse fracture risks

Review

Addressing the age-related needs of osteoporotic patients with strontium ranelate

Review

Microarchitecture in focus

Editorial

Fracture prevention in osteoporosis: assessing risks, providing solutions

Review

Comparing and contrasting the effects of strontium ranelate and other osteoporosis drugs on microarchitecture

Arthropedia

Grundlagenwissen der Arthroskopie und Gelenkchirurgie. Erweitert durch Fallbeispiele, Videos und Abbildungen. 
» Jetzt entdecken

Neu im Fachgebiet Orthopädie und Unfallchirurgie

18.04.2024 | Wirbelsäulenmetastase | Nachrichten

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

16.04.2024 | Spondylitis ankylosans | Nachrichten

Vorsicht mit hohen NSAR-Dosen bei ankylosierender Spondylitis!

15.04.2024 | Knie-TEP | Nachrichten

Brustkrebs in der Vorgeschichte macht Gelenkersatz komplikationsträchtiger

11.04.2024 | Spondyloarthritiden | Nachrichten

Zwei neue Alternativen zu TNF-Inhibitoren bei axSpA
weitere anzeigen

Update Orthopädie und Unfallchirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise